Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Highland Therapeutics, Inc.

http://highlandtherapeutics.com

Latest From Highland Therapeutics, Inc.

L’Oreal Defeats Slack-Fill Case In New York, Pivots To Clarisonic ‘Defect’ Complaint In California

L’Oreal USA beat a suit in May in New York regarding liquid cosmetics packaging, which plaintiffs alleged cheated consumers out of product they expected to be accessible, only to face a newly proposed class action, filed in California on 5 June, over an alleged Clarisonic waterproofing defect.

United States Beauty

Ulta On Q1 COVID-19 Impact; ‘Illegal And Ineffective’ Hand Sanitizers In Europe; More Cosmetics News

Ulta Beauty says sales are roughly flat in the first 180 stores it reopened following the COVID-19 shutdown, which dragged down its net sales roughly 33% in the fiscal 2020 first quarter. More cosmetics news in brief.

Beauty Sales & Earnings

Plaintiff Claims Against Beiersdorf For ‘Unlawfully Marketed Drug’ Are Preempted By FDCA, Court Rules

After five and a half years, three dismissal motions and one appeal, Beiersdorf’s prevailed on 15 April by summary judgment in a proposed class action alleging that its Nivea Skin Firming Hydration Body Lotion is an unlawfully marketed drug. Of course, the plaintiff still could appeal.

United States Legal Issues

Beiersdorf’s Long Court Battle Over Nivea ‘Drug’ Claims May Be Ending; In Similar Case, L’Oreal May Settle

The Beiersdorf and L’Oreal cases, both pending in California federal courts, have important implications for the cosmetics industry and its use of benefit claims that test statutory boundaries between unapproved drug products and cosmetics.

United States Legal Issues
See All

Company Information

UsernamePublicRestriction

Register